Celgene nabs FDA approval for blockbuster hopeful anemia med Reblozyl

celgene
Celgene's Reblozyl nabbed an FDA approval to treat anemia Friday. (Celgene)

Bristol-Myers Squibb's $74 billion pending pickup of Celgene has notched a win already with an FDA approval for JAK med Inrebic. Now, the consummation has grabbed another victory with an approval for a Celgene blood disease candidate––and it could spell blockbuster sales ahead.

The FDA Friday approved Celgene's Reblozyl (luspatercept), a novel erythroid maturation agent used to treat anemia in patients with beta thalassemia who require regular red blood cell transfusions. Though these transfusions are a lifesaving treatment, they can eventually lead to iron overload that can cause organ failure and shorten a patient’s life span. 

Reblozyl, co-developed with Cambridge, Massachusetts-based biotech Acceleron, is now the first FDA-approved treatment for anemia in beta thalassemia. The drug is expected to be ready for sale in one week, Celgene said. 

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

The FDA's nod was based on phase 3 data showing Reblozyl significantly increased the number of patients who required fewer blood transfusions over placebo in a 24-week period.

Celgene's drug will come with label warnings for thrombosis, or blood clots, hypertension and embryo-fetal toxicity, the company said. Serious adverse effects, including cerebrovascular accident and deep vein thrombosis, were reported in 1% of trial patients, and one patient reportedly died during clinical testing due to an unconfirmed case of acute myeloid leukemia, Celgene said.

RELATED: In a much-needed positive for BMS, Celgene gains FDA review for blockbuster hopeful

Reblozyl comes with blockbuster hopes, with Jefferies analysts forecasting $2 billion in peak annual sales for the drug if it gets a positive nod from the FDA in April to treat myelodysplastic syndromes.

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.